![Lotfi Yelles Chaouche](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lotfi Yelles Chaouche
Director/Miembro de la Junta en Apaxen SA .
Cargos activos de Lotfi Yelles Chaouche
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Theodorus Investment Funds
![]() Theodorus Investment Funds Investment ManagersFinance Theodorus Investment Funds is a venture capital firm founded in 2003. The firm headquartered in Brussels, Belgium. | Inversor de Capital Privado | 01/09/2017 | - |
Inhatarget Therapeutics
![]() Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Director/Miembro de la Junta | - | - |
Apaxen SA
![]() Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Director/Miembro de la Junta | 29/07/2019 | - |
NeuVasQ Biotechnologies SA
![]() NeuVasQ Biotechnologies SA Pharmaceuticals: MajorHealth Technology NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke. | Director/Miembro de la Junta | - | - |
Gepeceron SARL | Director/Miembro de la Junta | - | - |
Historial de carrera de Lotfi Yelles Chaouche
Antiguos cargos conocidos de Lotfi Yelles Chaouche.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
THERAVET SA | Director/Miembro de la Junta | 01/10/2020 | 01/04/2021 |
Presidente | 01/04/2021 | 20/12/2021 | |
ChromaCure SA
![]() ChromaCure SA Pharmaceuticals: MajorHealth Technology ChromaCure SA develops therapeutic molecules to fight against cancer. The company is based in Charleroi, Belgium. The Belgian company was founded in 2018 by Cedric Blanpain, who has been the CEO since 2018. | Director/Miembro de la Junta | - | - |
Formación de Lotfi Yelles Chaouche.
Institut Supérieur de l'Aéronautique et de l'Espace | Graduate Degree |
Estadísticas
Internacional
Bélgica | 8 |
Francia | 2 |
Operativa
Director/Board Member | 6 |
Private Equity Investor | 1 |
Chairman | 1 |
Sectorial
Health Technology | 5 |
Finance | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
THERAVET SA | Commercial Services |
Empresas privadas | 6 |
---|---|
Theodorus Investment Funds
![]() Theodorus Investment Funds Investment ManagersFinance Theodorus Investment Funds is a venture capital firm founded in 2003. The firm headquartered in Brussels, Belgium. | Finance |
ChromaCure SA
![]() ChromaCure SA Pharmaceuticals: MajorHealth Technology ChromaCure SA develops therapeutic molecules to fight against cancer. The company is based in Charleroi, Belgium. The Belgian company was founded in 2018 by Cedric Blanpain, who has been the CEO since 2018. | Health Technology |
Inhatarget Therapeutics
![]() Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Health Technology |
Apaxen SA
![]() Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Health Technology |
NeuVasQ Biotechnologies SA
![]() NeuVasQ Biotechnologies SA Pharmaceuticals: MajorHealth Technology NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke. | Health Technology |
Gepeceron SARL |